Case Summary:

“Prostate cancer is among the most prevalent diseases in the world for aging males, the second most common type of cancer in men overall, and the fifth leading cause of death worldwide. [The client], a molecular biology researcher specializing in prostate cancer whose novel developments in the diagnosis and treatment of mCRPC have already made significant and highly valuable contributions to the field.”

“In the United States, prostate cancer is a highly prevalent disease that affects one in eight men in their lifetimes and currently represents the second leading cause of cancer deaths among men. [The client’s] work directly addresses these critical concerns through the development of novel non-invasive biomarker detection and treatment protocols. These developments allow for individualized treatments for mCRPC patients, which results in improved patient outcomes and enhanced quality of life.”

These are two selected passages from letters of recommendation written for a postdoctoral research fellow in molecular biology from Japan. She held a Ph.D. in urology and wanted to continue her work in the United States for which she needed to file an NIW (National Interest Waiver) petition. Our team signed the retainer agreement with her, collected information from her academic and professional documents, and found the following:

• As an expert in the field of molecular biology, her proposed endeavor is to continue to develop liquid-based, non-invasive biomarker identification and cancer treatment strategies to advance innovations in the care of prostate cancer patients.
• Her research is of great importance because it addresses one of the world’s primary health concerns. Prostate cancer is known to be the fourth most common cancer throughout the global population and the second most common in men.
• Her research also improves the methodologies for detecting and treating prostate cancer, thereby improving the length and quality of life for the patients and reducing associated expenses.
• Her proposed endeavor also has broad implications for the United States, since, in America alone, nearly 250,000 new cases of prostate cancer are diagnosed each year. Furthermore, more than 34,000 Americans lose their lives to this disease, cementing prostate cancer as the second leading cause of cancer death among American men.
• Her research contributes to earlier detection technologies and improves treatment strategies for standard and mCRPC patients, increasing the lifespan of the millions of U.S. citizens suffering from prostate cancer. Her research directly supports national efforts to minimize the incidence and mortality of prostate cancer, revealing that it holds immense and immediate applicability in promoting national health outcomes.
• She has completed at least 9 reviews to date, and her work has resulted in 16 peer-reviewed journal articles (5 of them first-authored) and 1 book chapter.
• These publications have been cited a total of 190 times according to Google Scholar.
• Finally, her work in the area has stretched to over 12 years which means that she holds vast experience in the area.

These pieces of evidence thus helped us to show that her research on prostate cancer treatments holds significant value for U.S. public health, considering that millions of Americans require treatment for prostate cancer each year. This is exactly what won her approval. We are glad to have worked with her and won this case. We send our warmest regards and wish her the best in future endeavors.